Publications by authors named "Xavier Rabasseda"

41 Publications

Letter From The Editor.

Authors:
Xavier Rabasseda

Drugs Today (Barc) 2016 Jan;52(1)

View Article and Find Full Text PDF

Download full-text PDF

Source
January 2016

Letter from the editor.

Authors:
Xavier Rabasseda

Drugs Today (Barc) 2015 Apr;51(4):221

View Article and Find Full Text PDF

Download full-text PDF

Source
April 2015

Letter from the editor.

Authors:
Xavier Rabasseda

Drugs Today (Barc) 2015 Jan;51(1)

View Article and Find Full Text PDF

Download full-text PDF

Source
January 2015

A report from the 164th American Psychiatric Association (May 14-18, 2011 - Honolulu, Hawai'i, U.S.A.).

Authors:
Xavier Rabasseda

Drugs Today (Barc) 2011 Aug;47(8):625-44

Medical Department, Thomson Reuters, Barcelona, Spain.

Although tradition mandates that men should be dressed up in colorless attires, why do men visiting Hawai'i run to the first Aloha shop right after landing to get a multicolored flowery shirt, with a lei flower or kukui tree nut necklace to go with it? The answer to this question could be very complex, but psychiatrists attending this year's American Psychiatric Association meeting in the Honolulu Convention Center acted in a not dissimilar way by running to the new research poster and educational oral sessions of the meeting to learn new colors to paint the life of their patients with. And many colors, or at least an ample variety of treatment modalities, were discussed throughout the 5-day convention, including, notably, a number of innovative drugs with the capability of improving the functioning and quality of life of individuals suffering from psychosis, depression and a broad range of psychiatric diseases. The following report summarizes the main findings from clinical and experimental studies related to new psychiatric pharmacotherapies as reported and discussed during the meeting.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2011.47.8.1667109DOI Listing
August 2011

A report from the XVIII International AIDS Conference. (July 18-23, 2010-Vienna, Austria).

Authors:
Xavier Rabasseda

Drugs Today (Barc) 2010 Dec;46(12):945-57

Thomson Reuters, Barcelona, Spain.

Political and social issues have a major impact on how and when HIV infection and AIDS are treated, and were a major component of the meeting in Vienna. Many discussions were held on aspects such as epidemiology, risk behavior, public health, human rights, political responses to the epidemics challenge, social stigma and discrimination, use of and recommendations on the use of condoms and other preventive measures... However, the availability of drugs and/or other therapies is a crucial issue, and while it was not the main focus of attention during this year's international AIDS conference, it will be the focus of the following report. Indeed, intensive research for new antiretrovirals continues, with new active compounds presented during the poster sessions at the Wien Messe convention center, but a wide armamentarium is currently already available, including late-generation agents such as darunavir, etravirine, raltegravir and maraviroc that provide reliable effectiveness as rescue therapy for patients failing older drug-containing highly active regimens (Azkune Galparsoro, H. et al., Abst THPE0141). All information across the meeting related to therapies for HIV infection are briefly reviewed in the following report, which complements and guides through the extensive information available on the organizing society's website.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2010.46.12.1586465DOI Listing
December 2010

[Fingolimod in the treatment of multiple sclerosis. Novelties presented at the annual congress of the American Academy of Neurology (Toronto, April 2010)].

Authors:
Xavier Rabasseda

Drugs Today (Barc) 2010 Jul;46 Suppl D:1-14

Prous Science, Thomson Reuters, Barcelona, Spain.

Fingolimod, a sphingosine 1-phosphate receptor modulator, is currently on registration as an oral treatment for relapsing-remitting multiple sclerosis in the European Union and United States of America. New and important information on the drug was presented during the annual meeting of the American Academy of Neurology held in Toronto in April 2010, including, notably, results from the TRANSFORMS and FREEDOMS studies that, besides confirming the therapeutic benefit of the drug as a first-line therapy for multiple sclerosis, with superiority over interferon beta1a on clinical, inflammatory and functional outcomes, confirmed the safety and tolerability of the agent and described a specific benefit on the patients' functional abilities performing daily tasks. With additional new information on safety and tolerability and some new insight into the mechanism of action of fingolimod, new information presented during the meeting further supported the role of the drug in the treatment of multiple sclerosis and renewed hope for treating patients with a new therapeutic tool.
View Article and Find Full Text PDF

Download full-text PDF

Source
July 2010

Contentious controversies: a report from the 3rd World Congress on Controversies in Urology (February 25-28, 2010, Athens, Greece).

Authors:
Xavier Rabasseda

Drugs Today (Barc) 2010 Apr;46(4):291-6

Medical Department, Thomson Reuters, Barcelona, Spain.

The 3rd World Congress on Controversies in Urology held in Athens earlier this year offered a renewed opportunity to discuss many divisive issues in urology, most notably urinary incontinence and prostate cancer, which were the two main topics of discussion. The following is a review of major topics directly related to urological therapy as presented during the meeting.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2010.46.4.1497396DOI Listing
April 2010

Marching against blood diseases: a report from the 51st Annual Meeting of the American Society of Hematology (December 5-8, 2009 - New Orleans, Lousiana, USA).

Authors:
Xavier Rabasseda

Drugs Today (Barc) 2010 Mar;46(3):195-230

Medical Department, Thomson Reuters, Provença 388, Barcelona, Spain.

Lymphoma, leukemia, myeloma and many other malignant and nonmalignant blood diseases can have a severe impact on the sufferer's life expectancy, quality of life and functional abilities, and require treatment that in many cases is restricted to drug therapy. Many other issues were discussed during last year's American Society of Hematology annual meeting, but important information was also reported and discussed on possibilities for modifying the life cycle of blood cells as a pharmacological strategy aimed at addressing the abnormalities that result in hematological disease for improving the resulting signs and symptoms. New insight into such pharmacological approaches discussed during the meeting in New Orleans are summarized in the following report, which complements full detailed information contained in the original meeting abstracts available on the society's website.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2010.46.3.1490753DOI Listing
March 2010

New music to an old melody: The 66th AAAAI meeting in New Orleans.

Authors:
Xavier Rabasseda

Drug News Perspect 2010 Apr;23(3):211-5

Thomson Reuters, Barcelona, Spain.

With the images of the earthquake in Haiti still fresh in the memory, and a similar disaster just occurring in Chile, coming again to New Orleans brought back vivid images of the Hurricane Katrina disaster. The city has for the most part recovered from that experience, although molds persist in many historical and ancient buildings, putting allergy sufferers at risk as they breathe in allergens. The city of New Orleans is almost fully restored to its former glory, however, and music again pours out through doors and windows of the French Quarter, calling people in to share drinks and food while clearly stating which specific products contain or may contain traces of nuts, so that people with allergies do not need to run to their epinephrine autoinjector to treat life-threatening anaphylactic attacks. Against this background, and under heavy, rainy and windy skies, the American Academy of Asthma, Allergy and Immunology (AAAAI) held its 2010 annual meeting in the Ernst E. Memorial Convention Center, where 4 days packed with presentations and discussions displaced most other thoughts from the attendees' minds. Indeed, nights on Bourbon Street had never been so uncrowded as they were during the meeting, suggesting that attendees were perhaps sequestered in their hotel rooms, working with new information obtained at the meeting.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1358/dnp.2010.23.3.1489982DOI Listing
April 2010

Highlights from the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Authors:
Xavier Rabasseda

Drugs Today (Barc) 2010 Jan;46(1):49-67

Medical Department, Thomson Reuters, Barcelona, Spain.

The Rhine river was the scenario of this year's congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in the Dusseldorf Messe right beside the river in September 9-12, 2009. The meeting contained a number of important new contributions with a direct impact in how patients are and can be treated in the current clinical setting.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2010.46.1.1459657DOI Listing
January 2010

Focus on neurologic diseases: a report from the 59th American Academy of Neurology annual meeting.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2007 May 9;11:E13. Epub 2007 May 9.

Prous Science, Barcelona, Spain.

View Article and Find Full Text PDF

Download full-text PDF

Source
May 2007

Clinical studies presented at major international meetings in 2006.

Authors:
Xavier Rabasseda

Methods Find Exp Clin Pharmacol 2007 Mar;29(2):113-51

Prous Science Medical Information Department, Barcelona, Spain.

View Article and Find Full Text PDF

Download full-text PDF

Source
March 2007

A report from the 31st European Society of Medical Oncology congress.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2006 Nov 28;10:E32. Epub 2006 Nov 28.

Prous Science Medical Information Department.

View Article and Find Full Text PDF

Download full-text PDF

Source
November 2006

Cardiovascular pharmacotherapy: a report from the 55th annual scientific sessions of the American College of Cardiology.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2006 Apr 4;10:E12. Epub 2006 Apr 4.

Prous Science Medical Information Department.

View Article and Find Full Text PDF

Download full-text PDF

Source
April 2006

Hot topics in cardiology: a report from the 2005 meeting of the European Society of Cardiology.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2005 Oct 14;9:E28. Epub 2005 Oct 14.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
October 2005

News in hypertension management: a report from the 15th European Meeting on Hypertension.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2005 Aug 4;9:E22. Epub 2005 Aug 4.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
August 2005

Newsbites on diabetes and diabetes therapy: a report from the 65th Scientific Sessions of the American Diabetes Association.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2005 Jul 29;9:E21. Epub 2005 Jul 29.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
July 2005

Modern therapy for hypertension and related disorders: a report from the 20th Annual Scientific Meeting of the American Society of Hypertension. May 14-18, 2005. San Francisco, California, USA.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2005 Jun 2;9:E19. Epub 2005 Jun 2.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
June 2005

Enhanced hypercholesterolemia therapy: the ezetimibe/simvastatin tablet.

Drugs Today (Barc) 2005 May;41(5):317-27

Medical Information Department, Prous Science, Barcelona, Spain.

While therapy with HMG-CoA reductase inhibitors, or statins, has provided the principal pharmacological innovation in the treatment of hypercholesterolemia in recent years, extensive use of these agents has shown that not all patients respond to them and that still greater reductions in low-density lipoprotein (LDL) cholesterol can further protect patients from cardiovascular events. The strategy of increasing the doses of statins is effective but associated with an increase in adverse effects. The combination of statins with other agents has also, in some cases, increased efficacy, but has likewise been limited by toxicity. The administration of a new agent with a novel mechanism of action, ezetimibe, with a well-characterized and effective statin, simvastatin, in a single tablet now appears to provide enhanced treatment without compromising safety. Monotherapy with either ezetimibe or simvastatin has demonstrated the ability to significantly lower LDL cholesterol. Simultaneous administration of the two agents benefits from their two distinct mechanisms of action: inhibition of biliary and dietary cholesterol absorption by ezetimibe and inhibition of hepatic cholesterol synthesis by simvastatin. The two mechanisms have exhibited complementary activity in preclinical evaluation and have demonstrated an absence of pharmacokinetic interaction in humans. Large clinical trials have consistently shown that the addition of ezetimibe to simvastatin produces significantly greater reductions in LDL cholesterol than simvastatin alone, with tolerability similar to statin monotherapy. Ezetimibe/simvastatin has also been associated with other beneficial effects on lipids, and it achieves greater efficacy than monotherapy with the use of lower, safer doses of the statin. These findings indicate that use of the ezetimibe/simvastatin single tablet will allow more patients to meet increasingly stringent LDL cholesterol goals, thereby avoiding negative cardiovascular outcomes.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2005.41.5.893614DOI Listing
May 2005

Advances in atherosclerosis: new treatments, new targets. A report from the 75th European Atherosclerosis Society Annual Meeting.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2005 May 12;9:E14. Epub 2005 May 12.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
May 2005

Insights into cardiovascular therapy: a report from the 2005 Annual Meeting of the American College of Cardiology.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2005 Apr 11;9:E12. Epub 2005 Apr 11.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
April 2005

Tegaserod: a serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome.

Drugs Today (Barc) 2004 Dec;40(12):1013-30

Medical Information Department, Prous Science, Provença 388, 08025 Barcelona, Spain.

Activation of serotonin 5-HT(4) receptors has been proposed as treatment for irritable bowel syndrome, a common, complex and distressing gastrointestinal disorder. Abnormal intestinal motility and sensitivity in irritable bowel syndrome patients can result in diarrhea, constipation, abdominal pain, bloating, headache and fatigue; these and other symptoms can lead to exacerbation of psychological stress, which may in turn induce further physiological abnormalities and patient discomfort. The serotonin agonist tegaserod binds with high affinity to 5-HT(4) receptors and has demonstrated potent pharmacological effects on the mid- and distal gut. Tegaserod has been safely employed in clinical trials where it has demonstrated efficacy in normalizing intestinal function, thereby improving irritable bowel syndrome symptoms.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2004.40.12.872576DOI Listing
December 2004

New research in cardiology: a report from the American Heart Association Scientific Sessions 2004.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2004 Dec 1;8:E12. Epub 2004 Dec 1.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
December 2004

Quetiapine in bipolar disorder: Increasing evidence of efficacy and tolerability.

Drugs Today (Barc) 2004 Oct;40(10):837-52

Medical Information Department, Prous Science, Provença 388, Barcelona 08025, Spain.

Quetiapine is an atypical antipsychotic agent that has been approved for the treatment of schizophrenia in over 75 countries; it has been used to treat more than 4 million individuals since its launch in 1997. After quetiapine was found to improve mood and reduce aggression in patients with schizophrenia, researchers began investigating the drug in other indications. Quetiapine, as monotherapy or combined with mood stabilizers, significantly reduces measures of disease severity and acute mania in a variety of bipolar disorder patients, and displays excellent tolerability for a drug in its class. Of particular note is the incidence of extrapyramidal symptoms at levels similar to those seen with placebo. A phase III trial program in bipolar disorder is presently ongoing and includes five randomized, double-blind, controlled trials already reported and several other studies which are ongoing or planned.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2004.40.10.863744DOI Listing
October 2004

Moving cardiovascular pharmacotherapy: a report of poster presentations during the European Society of Cardiology 2004 Annual Congress.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2004 Oct 1;8:E9. Epub 2004 Oct 1.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
October 2004

Highlights from the 74th Congress of the European Atherosclerosis Society.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2004 May 1;8:E3. Epub 2004 May 1.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
May 2004

Moving drug therapies in cardiology: summary of presentations at the American College of Cardiology Scientific Session 2004.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2004 Mar 22;8:E2. Epub 2004 Mar 22.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
March 2004

Treatment of hypertension in 2004: new research disclosed during the Annual Meeting of the American Society of Hypertension.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2004 Jul 1;8:E5. Epub 2004 Jul 1.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
July 2004

Advances in the treatment of hypertension: a report from the XIV Annual Meeting of the European Society of Hypertension.

Authors:
Xavier Rabasseda

Timely Top Med Cardiovasc Dis 2004 Aug 18;8:E7. Epub 2004 Aug 18.

Medical Information Department, Prous Science.

View Article and Find Full Text PDF

Download full-text PDF

Source
August 2004
-->